Heart failure & cardiomyopathiesDiagnostic or prognostic study
Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography/Computed Tomography
- Diagnostic accuracy study
Authors' conclusion
124I-evuzamitide PET/CT imaging can identify myocardial amyloid in variant transthyretin allele carriers and wild-type subjects when 99mTc-pyrophosphate does not.
Study context
- Population
- Patients with wild-type ATTR-CA and ATTR variant-allele carriers
- Participants
- 25 patients
- Comparison
- 124I-evuzamitide positron emission tomographic (PET)/computed tomographic (CT) vs 99mTc-pyrophosphate scintigraphy
- Wild-type ATTR-CAn = 7
- ATTR variant-allele carriersn = 18
- Outcome
- Myocardial 124I-evuzamitide PET uptake and diagnostic performance vs 99mTc-pyrophosphate
Performance
As reported in the abstract
Subjects with ATTR and Perugini grade 0 or 1 99mTc-pyrophosphate scans with cardiac 124I-evuzamitide uptake
11
Myocardial uptake in variant ATTR with biopsy-proven disease
5
Myocardial uptake in wild-type ATTR with grade 0 99mTc-pyrophosphate scans but extracardiac biopsies showing ATTR
2
Further findings
Correlation of myocardial amyloid load
- Moderately to strongly correlated with disease stage and with echocardiographic and quality-of-life measures
Original publication
Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography/Computed Tomography. JACC Cardiovasc Imaging. Published 28 May 2025. doi:10.1016/j.jcmg.2025.01.018
Summarised from the published abstract; every number is checked against it